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Abstract Inhaled nitric oxide (iNO)
was first used in neonatal practice in
1992 and has subsequently been used
extensively in the management of
neonates and children with car-
diorespiratory failure. This paper as-
sesses evidence for the use of iNO in
this population as presented to a
consensus meeting jointly organised
by the European Society of Paediatric
and Neonatal Intensive Care, the
European Society of Paediatric Re-
search and the European Society of
Neonatology. Consensus Guidelines
on the Use of iNO in Neonates and
Children were produced following
discussion of the evidence at the
consensus meeting.
Keywords Inhaled nitric oxide ·
Pulmonary hypertension · Persistent
pulmonary hypertension of the
newborn · Extracorporeal membrane
oxygenation · Vasodilator ·
Pulmonary
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Introduction
Inhaled nitric oxide (iNO) has been used in Europe to
treat a variety of conditions in neonates and children since
1992, foremost in persistent pulmonary hypertension of
the newborn (PPHN), which has remained a major
therapeutic challenge in the NICU [1, 2]. Introduction
of iNO into clinical use was virtually unregulated in
Europe, where supplies of industrially produced gas were
freely available. Subsequently clinical trials have estab-
lished roles for iNO therapy in the treatment of term
neonates with severe respiratory failure and a pharma-
ceutical quality product has recently become available in
Europe and the United States. The high cost of the
licensed product, compared to previous industrial sup-
plies, and the narrow scope of the drug’s licensed
indications suggested to our group that a consensus
should be established on the use of iNO therapy in
neonates and children covering both its approved and
potential indications.
Methods
An Advisory Board was established under the auspices of the
European Society of Neonatal and Paediatric Intensive Care to co-
ordinate the scientific programme of the meeting. The board
consisted of experts with proven scientific or clinical expertise
relevant to the clinical use of iNO. The board identified a further
panel of experts who were invited to act as section leaders whose
role was to review the literature in their designated subject area.
Section leaders were asked to produce written summaries of their
subject area, which were then circulated to delegates prior to the
meeting and which formed the basis of the evidence presented to
delegates at the consensus meeting itself.
A further panel of opinion leaders were invited to attend the
meeting on the basis of their known interest in the use of iNO or
their status as opinion leaders in the field of neonatal and paediatric
intensive care. The European Society of Paediatric Research and
the European Society of Neonatology were officially represented at
the meeting. At the consensus meeting each subject area was
presented in summary by the section leader(s), following which
open discussion led to the composition of draft consensus
statements. These were then edited and re-presented to delegates
with further discussion leading to final agreement on the individual
consensus statements.
Results
Inhaled nitric oxide in term and near-term neonates
Neonatal hypoxaemia may result from intra-pulmonary
shunting, from extra-pulmonary shunting (so-called
PPHN) or from cyanotic congenital heart disease. The
presence of interstitial pulmonary infiltrates or a low
volume lung (<6–7 ribs) on chest X-ray strongly suggests
parenchymal lung disease. Alveolar recruitment has been
shown to render babies with severe hypoxaemic respira-
tory failure responsive to iNO, when they were previously
unresponsive [2]. Exogenous surfactant and ventilatory
manoeuvres [3] should therefore be deployed to optimise
lung volume before iNO is introduced. If cyanosis persists
after any necessary lung recruitment manoeuvres have
been applied, an echocardiogram should be obtained to
confirm or exclude the presence of congenital heart
disease or pulmonary hypertension as causes of cyanosis.
Inhaled NO is most likely to benefit babies with PPHN
with recruited lung volume and is unlikely to benefit
babies with cyanotic heart disease.
The recent Cochrane Review was used as a framework
in this discussion [4]. The review, last updated in
December 2000, included 12 relevant trials in its analysis,
all of which used random allocation [5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15]. One further on-going study received
limited analysis since, at the time of review, it was on-
going and published only as an abstract [16]. A literature
search up to October 2003 failed to reveal any new
randomised, controlled trials not already included in the
Cochrane review.
The limitations of the studies presented within the
Cochrane review were highlighted. Of major importance,
the entry criteria differed markedly between trials as did
dosage and ventilatory strategies, there being a suggestion
that high frequency oscillatory ventilation (HFOV)
appears beneficial in achieving a response to iNO [10].
Eight of the 12 clinical trials studied the effect of iNO on
the overall clinical course of the babies included and, in
particular, whether the need for extracorporeal membrane
oxygenation (ECMO) was reduced. Only six trials did not
allow crossover [6, 7, 8, 11, 12, 13]. Of the six studies
which did not allow crossover, three [6, 11, 12] found a
statistically significant reduction in the combined out-
come of death or requirement for ECMO in the NO group.
A meta-analysis of all six studies found that iNO
treatment resulted in a reduction in the incidence of
death or requirement for ECMO (relative risk 0.65) [4].
Inhaled nitric oxide therefore appears to improve
outcome in hypoxaemic term and near-term infants. The
improvement is due mainly to a reduction in the need for
ECMO, since mortality was not reduced. The two largest
studies [6, 11] included infants with congenital diaphrag-
matic hernia as sub-groups. A separate analysis has been
presented from one of these studies [17]. There was no
evidence that outcome was improved in these babies
through the use of iNO, even if short-term improvements
in oxygenation did occur. It is important to note that
whilst iNO reduced the need for ECMO, the majority of
mature babies in these studies went on to ECMO.
Only one study has considered long-term follow-up as
a primary or secondary hypothesis. In this study, the
incidence of disability, the incidence of deafness and
infant development scores were all similar between tested
survivors who received NO and those who did not [18].
The major randomised, controlled trials of iNO in term
or near-term babies have used echocardiography to
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exclude congenital heart disease as a cause of hypox-
aemia prior to exposure to iNO. Babies with such lesions
are at best unlikely to benefit from iNO, as cyanosis is due
to extra-pulmonary shunting. Inhaled NO exposure may
even be harmful in some babies with congenital heart
disease, such as those with obstructed total anomalous
pulmonary venous drainage or severe left ventricular
dysfunction with right-to-left ductal shunting [19], in
whom pulmonary arteriolar vasoconstriction may be
clinically beneficial by reducing left heart filling.
Dosage and response to inhaled nitric oxide treatment
in term and near-term neonates
Decisions regarding continued use of iNO therapy cannot
be based on the primary end points used in the pivotal
studies, such as reduced mortality or ‘avoidance’ of
ECMO. Instead clinicians must use surrogate physiolog-
ical end points in order to establish whether an initial test
exposure to iNO is effective. Improvement in oxygen-
ation of approximately 20% over baseline values at 30–
60 min has been used in many studies as an indicator of
early response to iNO including six of the studies in the
Cochrane review [5, 6, 7, 9, 11, 12].
Four published studies have reported dose-response
data for this group of babies [7, 20, 21, 22]. All four
studies suggest that a maximal beneficial effect of iNO is
already seen at concentrations of less than 30 ppm.
Further increases of iNO (to 80–100 ppm) do not appear
to result in further improvement of oxygenation above
that achieved at 20–30 ppm. The large NINOS study [11]
used initial doses of 20 ppm iNO, but exposed ‘partial
responders’ to 80 ppm. Only 6% of these partial
responders were converted to full response by 80 ppm
iNO.
In the small study published by Tworetzky et al. a
maximum reduction of pulmonary artery pressure was
observed at 20 ppm NO, whereas maximal improvement
in oxygenation occurred at 5 ppm [23]. Response to the
introduction of iNO usually occurs rapidly in ‘respon-
ders’. Some investigators attribute clinical improvements
seen several hours later to iNO administration [24].
However it was the expert group’s view that there is a
serious danger that babies with very severe hypoxaemia
could be harmed if ECMO referral were to be delayed
whilst waiting for a ‘late’ response.
If no substantial effect has been achieved during a trial
of iNO, treatment with iNO should be rapidly discontin-
ued or the baby transferred on iNO to a level 3 or tertiary
neonatal unit. This should occur as soon as the clinician is
convinced that iNO is not inducing a beneficial effect
judged by improving oxygenation. The trial to improve
oxygenation with NO should not last longer than 4 h. The
reason not to prolong NO therapy unnecessarily is that
NO synthase is down-regulated, with suppression of
endogenous NO production. Down-regulation of endog-
enous NO synthase by the use of iNO has been suggested
[25, 26, 27].
We were unable to identify studies establishing the
optimal regime for maintenance of iNO therapy once an
initial response has been established. It is, however,
logical in clinical practice to seek to minimise iNO
exposure by lowering the iNO dose, provided the
beneficial effects on oxygenation and general clinical
stability are maintained. This approach was described by
Kinsella et al. [28] in the early stages of the clinical
exploration of iNO therapy and further validated by Clark
et al. [6].
Discontinuation and weaning
Some information is available on strategies for weaning
patients from iNO as clinical improvement occurs. In a
prospective study, Demirakca et al. evaluated the clinical
response to iNO in neonates and children with acute
respiratory distress syndrome (ARDS) [21]. Attempts to
discontinue iNO were made as soon as a stable respiratory
status (PEEP<6 cmH2O, inspiration/expiration ratio of
1:2, FiO2 <0.8 and an iNO concentration of 5 ppm) had
been achieved. Oxygenation index (OI) values of less
than 5 predicted successful withdrawal with a sensitivity
of 75%, a specificity of 89%, a positive predicted value of
69% and a negative predictive value of 91% [21].
Aly et al. [29] adopted a weaning strategy for babies
with PPHN which included step-wise 5 ppm decrements
of iNO doses. Discontinuation of iNO was performed as
soon as the patient was stable with an FiO2 less than 0.5.
Weaning was successful at the first attempt in 9 out of 16
patients. In the remaining seven neonates, major signs of
deterioration (oxygen saturation drop >10% or below
85%) prompted a reinstitution of iNO treatment for
30 min. Subsequently, FiO2 was raised by 0.4 and a
successful withdrawal of iNO was then obtained. Inter-
estingly, FiO2 could be returned to the pre-weaning value
in a few hours. Sokol et al. [30] noted that significant
deterioration of PaO2 occurred in some babies even when
weaned from 1 to 0 ppm, suggesting that iNO is
physiologically active even at very low concentrations.
There may be a role for other vasodilators such as
epoprostenol, iloprost, endothelin antagonists or selective
phosphodiesterase inhibitors [31] when weaning babies
from iNO after treatment courses of sufficient duration to
down-regulate NO synthase.
Toxicity
Nitric oxide reacts with oxygen to form nitrogen dioxide
(NO2) where the reaction rate is proportional to the square
of the NO concentration and directly proportional to the
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oxygen concentration. Whilst NO itself is a relatively
reactive molecule, NO2 is demonstrably more reactive
and toxic and is a radical (it has an unpaired electron).
Due to the fact that NO is usually administered in
combination with high inhaled oxygen concentrations and
that NO2 in animal experiments is damaging to the lungs
already at low concentrations when administered with
other oxidants, the main toxicological concern should be
focused on NO2 exposure and this should be kept to a
minimum. In long-term exposure lung damage may occur
at 0.5 ppm NO2 and acute lethal effects are seen from
100 ppm. Human subjects inhaling 2–3 ppm NO2 for 5 h
demonstrated reductions in antioxidant defences and an
increase in alveolar permeability [32]. Reactive species
such as peroxynitrite formed from NO2, as well as being
implicated in short-term toxicity, have the potential to
cause damage to DNA, raising the possibility of muta-
genic or carcinogenic effects. However, the concentra-
tions of iNO and NO2 to which patients are exposed
clinically are largely within the permitted limits for
occupational exposure [33]. There is as yet no evidence
that inhalation of NO has any lasting adverse effects.
Long-term follow-up of children exposed to iNO therapy
will be required to establish any late adverse effect.
When NO reacts with haemoglobin, methaemoglobin
(metHb) is formed. MetHb is not directly toxic, but is
unable to carry oxygen. If metHb is allowed to accumu-
late it can significantly reduce the oxygen-carrying
capacity of blood. The monitoring and management of
metHb during clinical iNO therapy is discussed below.
Inhalation of NO has been shown by some investiga-
tors [34], but not by others [35], to inhibit platelet
function. The randomised controlled neonatal trials have,
however, not shown any difference in bleeding compli-
cations between groups administered iNO or control gas
[4].
Delivery and monitoring
Nitric oxide administration systems should deliver con-
stant concentrations of iNO within the respiratory gas
mixture independent of ventilator mode or settings,
ensure a rapid mixing and minimise contact time between
NO and oxygen, thereby reducing the possibility of
generating high NO2 levels [36, 37, 38]. The delivery
system should display the pressure within the NO cylinder
to permit timely cylinder changes to be undertaken
without loss of gas supply. The system should ideally
encompass a backup power supply for use in the event of
mains failure or during intra-hospital transport. A manual
backup or ‘hand bagging’ facility must be provided for
use in the event of ventilator failure or other indications
for hand ventilation, as sudden discontinuation of iNO
therapy can be life-threatening [36, 37, 39].
The safest approach to iNO delivery is probably to use
only pharmaceutical grade NO stored in cylinders and at
concentrations and conditions approved by drug regula-
tory bodies and delivered by devices tested and approved
according to the appropriate medical device legislation.
In the clinical setting, measurement of iNO and NO2
concentrations can be undertaken using chemilumines-
cence or electrochemical devices. There are a number of
practical disadvantages of chemiluminescence analysers
in the clinical setting, including their high cost, their need
for relatively high sample volumes, noise, their need for
regular calibration and their relative inaccuracy in
measuring NO2 due to the “quenching” effect [37].
Electrochemical analysers use two separate fuel cell
sensors for NO and for NO2, placed either in the gas
mainstream or side stream of the ventilatory circuit.
Electrochemical devices do not underestimate NO2 levels,
are inexpensive, silent, easy to calibrate and require very
low gas sample volumes. Most devices are portable.
Electrochemical analysers are, however, relatively insen-
sitive (resolution 0.5 ppm) and their measurements may
be affected by temperature, pressure, humidity and the
presence of other gases in the environment [37]. Although
many early studies of iNO delivery systems were
constructed by investigators for their own studies, a
number of delivery and monitoring systems have been
developed for clinical use and are commercially available
[39, 40].
Inhaled NO2 concentrations should be kept to a
minimum. Clinical and experimental evidence show that
it is possible to administer 20 ppm iNO whilst generating
NO2 concentrations of less than 0.2 ppm [38]. Direct
comparisons with tolerable environmental NO2 concen-
trations should take into account that the awake person
inhaling NO2 is exposed to at least 50% lower NO2
concentrations in their trachea due to efficient scavenging
of NO2 in the upper airways.
Nitric oxide has been supplied for clinical use by a
number of suppliers as a compressed gas diluted in a
balance of nitrogen with final NO concentrations of
between 100 and 1000 ppm. The gas is supplied in
aluminium cylinders filled to pressures of 150–200 bar.
Very concentrated preparations may be difficult to deliver
accurately whilst mixtures with low NO concentrations
can reduce FiO2 excessively [41]. The final choice of
cylinder NO concentration will, therefore, depend on the
characteristics of the delivery system in use and the
required FiO2 and FiNO. The future availability of iNO as
a pharmaceutical within Europe may encourage standard-
isation.
Environmental safety
The US National Institute for Occupational Safety and
Health (NIOH) suggest a “Permitted Exposure Limit” for
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NO2 of 5 ppm and NO 25 ppm over an 8-h period for
these potentially toxic substances [33]. Several European
countries have regulated maximal occupational exposure
to 2 ppm NO2. Extrapolating this to the ICU in which iNO
would be administered for a 24-h period, it would be
prudent to aim for environmental levels of NO2 in the
ICU below 1.5 ppm. Environmental NO contamination
can occur from two sources during iNO administration:
dumped waste ventilator gas and accidental leakage of
concentrated gas from a delivery system or cylinder. The
US Food and Drug Administration state, in their speci-
fication for medical delivery of NO, that such delivery
“does not individually or cumulatively have a significant
effect on the human environment. Therefore, neither an
environmental assessment nor an environmental impact
statement is required” [42]. A similar ruling is applied by
the UK National Health Service, which states that
scavenging of waste NO is unnecessary provided that
ventilation in the ICU meets required standards [43].
Several studies confirm that this advice is sound [44, 45].
There must, however, be a small risk of high environ-
mental levels occurring from uncontrolled release of a
large volume of concentrated gas from a cylinder in the
event of a serious error or accident. For this reason, the
consensus group suggest that it is reasonable to measure
environmental levels of NO2 continuously.
Transport
In 30–50% of babies given a trial of iNO the therapy does
not result in a sustained positive oxygenation response
[4]. Most babies who fail to respond to iNO are potential
ECMO candidates. Since acute withdrawal of iNO may
be associated with severe rebound hypoxaemia, even in
babies who apparently respond poorly [46, 47], arrange-
ments must be in place for these babies to be transferred
to an ECMO centre without interruption of iNO delivery.
Occasionally non-neonates may require transport within
or between hospital whilst receiving iNO.
Apart from the ability to deliver iNO safely to the baby
during transport, consideration must also be given to
safety of the staff and crew within the transport vehicle,
and compliance with any regulations governing such use.
Kinsella et al. recently reported concentrations of NO and
NO2 in the cabin environment of various transport
vehicles during iNO use and confirmed them to be
negligible. Furthermore, they calculated the effects of
uncontrolled release of a full US D-type NO cylinder
containing 350 l NO gas. In this “ worst case scenario”
environmental NO levels were unlikely to reach danger-
ous levels (maximum 40 ppm fixed wing aircraft, 34 ppm
ground ambulance, 94 ppm small helicopter) [48].
The expert group recommend that equipment for
delivery and monitoring of iNO during transport should
comply with standards for medical devices and the safety
and test requirements of the specific aircraft or other
transport vehicle used. Several delivery systems have
been used during transport and at least two portable
systems are commercially available, one of which is
specifically designed as a transport system [48].
Staff training
Clinical use of iNO involves potential hazards for both
staff and patients, mainly from the risk of exposure to
toxic levels of NO and NO2, but also issues such as safe
handling of gas cylinders. The safe and appropriate use of
medical equipment requires adequate preparation and
training. Regulatory authorities frequently recommend
standards for training in the use of medical equipment,
typically stating that training should include both theo-
retical and practical instruction [49]. US guidelines for
neonatal use recommend physician training [50] and some
nursing authors have discussed the need for training [51].
It has also been recommended that protocols or guidelines
should be compiled by hospitals using iNO, covering all
aspects of its use including responsibility for off-label
prescription. Such protocols should aim to help staff
deliver iNO therapy that is both safe and effective [52].
Use of inhaled nitric oxide in preterm neonates
For the purposes of this paper, ‘preterm’ neonates are
defined as those babies too premature to be considered for
ECMO should their condition require it, i.e. babies less
than 34 weeks completed gestation [53].
Inhaled NO may improve oxygenation in preterm
neonates with hypoxaemic respiratory failure in one of
two ways: (1) it may reverse extra-pulmonary shunting by
selectively decreasing pulmonary vascular resistance
(PVR) and (2) it may reduce intra-pulmonary shunting
(and/or V/Q mismatch) by redistributing pulmonary blood
flow. The former mechanism is likely to be the most
important in infants with primary or secondary PPHN,
whereas the latter will be more important in the majority
of preterm infants who have parenchymal lung disease as
the primary cause of their hypoxaemic respiratory failure.
There are three published, randomised, controlled
trials (RCTs) of iNO therapy in preterm infants [14, 54,
55], overviews of which have been reported in the form of
two systematic reviews [53, 56]. A total of 207 infants
have been studied in these RCTs. Other RCTs (such as the
UK INNOVO trial, NICHD Preemie iNO trial and other
US trials) are either on-going or have only just completed
recruiting and results are not yet available. One small
RCT has reported the long-term neurodevelopmental
outcome following iNO therapy [57].
A Cochrane Review has summarised the results of the
three RCTs in preterm infants [53]. The study of Kinsella
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et al. [55] is the single most useful trial in that it recruited
neonates with hypoxaemic respiratory failure early in the
course of their respiratory disease, the intervention was
masked, an important primary outcome (mortality) was
chosen, there was no crossover treatment with iNO and
infants were carefully evaluated for intraventricular
haemorrhage (IVH). There is no evidence of an effect
of iNO on mortality or chronic lung disease (CLD) at
36 weeks, or on survival without CLD in preterm infants
with hypoxaemic respiratory failure. Doses of between 5–
20 ppm iNO appear to be effective in improving arterial
oxygenation within the first 2 h of treatment. One study
showed a reduction in days of ventilation with 5 ppm iNO
in survivors [55] whilst another study reported no
difference [14].
Sufficient data are lacking for evaluation of the
possible effects of iNO on periventricular haemorrhage
or on long-term neurodevelopmental outcome. Thus, with
the data currently available, the consensus group do not
recommend the routine use of iNO in the preterm infant
and strongly recommend its use in this indication only
within controlled clinical trials. The use of iNO could,
however, be justified as rescue therapy in life-threatening
hypoxaemia after lung recruitment has been optimised.
Use of inhaled nitric oxide in paediatric acute lung injury
and acute respiratory distress syndrome
Acute lung injury (ALI) or acute respiratory distress
syndrome (ARDS) may result from many systemic
disease processes, and affects people of all ages. No drug
therapy has been found to impact substantially on survival
in ALI cases. Inhaled NO has been used in this setting
principally because of its effect in improving oxygenation
as therapy commences, due to improved ventilation-
perfusion matching.
The comments in this section are aimed at guiding the
clinical use of iNO in paediatric practice. Recommenda-
tions on ALI and ARDS had to be formed on a very
limited base of information as, apart from case series and
anecdotes about children, almost all data on such clinical
use of iNO were only available for adult patient
populations. Five randomised controlled trials were
evaluated (Dellinger [58], Dobyns [59], Lundin [60],
Troncy [61], Michael [62]) in a recent Cochrane review
[63] assessing 535 patients, with only one trial focused on
children [59]. Inhaled NO had no impact on mortality in
trials without crossover (relative risk 0.98, 95% confi-
dence intervals 0.66, 1.44) or with crossover of treatment
failures to open-label iNO (RR 1.22, 95% CI 0.65, 2.29).
Evidence published in one study demonstrated that iNO
resulted in a transient improvement in oxygenation in the
first 24 h of treatment: the oxygenation index (OI) showed
a mean difference of 3 (95% CI 5.354, 0.646), and
PaO2/FiO2 ratio and a mean difference of 35 (95% CI
20.236–49.764) [58]. Other clinical indicators of effec-
tiveness, such as duration of hospital and intensive care
stay, were inconsistently reported. There were no com-
plications reported to be directly attributable to this
treatment.
Based on these data, it appears that iNO has no effect
on mortality and only transiently improves oxygenation in
ALI/ARDS. There is insufficient data to assess other end
points. The authors of the Cochrane review suggest that
any further trials of iNO in this indication must stratify for
underlying disease, since outcome is thought to be more
related to this than to respiratory failure alone.
Use of inhaled nitric oxide in children
with cardiac disease
Pulmonary hypertension is an important problem in many
children with acquired or congenital heart disease. As a
selective pulmonary vasodilator, as in neonatal PPHN,
iNO has the potential to improve the management of these
patients. Numerous reports of iNO usage in such patients
have been published including its use in the assessment of
the reversibility of pulmonary hypertension as a diagnos-
tic procedure [64, 65] and in the perioperative manage-
ment of pulmonary hypertension or RV afterload
reduction [66, 67, 68]. Inhaled NO has also been shown
to complement standard methods of differentiating reac-
tive from fixed pulmonary vascular disease [64, 65].
Inhaled NO has been shown to be effective in the
management of some patients with severe reactive
pulmonary hypertensive episodes following cardiac sur-
gery [69, 70]. In these patients, iNO is believed to replace
endogenous NO production, which is temporarily im-
paired due to the effects of cardiopulmonary bypass on
the pulmonary endothelium. One randomised, controlled
trial [71] reported that the prophylactic administration of
10 ppm iNO was associated with a significant reduction in
pulmonary hypertensive events and a reduction in time to
meeting extubation criteria. Mortality and length of ICU
stay were, however, unaffected. Another similar, but
smaller, study failed to demonstrate any benefit from
prophylactic iNO [72]. The view of the consensus
meeting experts was that data from other clinical trials
was required before the routine prophylactic use of iNO
could be recommended in children at risk of pulmonary
hypertensive events after repair of congenital heart
surgery. Inhaled NO has also been shown to improve
the haemodynamic status in patients with elevated PVR
after the Fontan operation [73] and in those with failing
right ventricles [74]. There are no RCT’s in this group of
patients.
In summary, there are few RCTs on the use of iNO in
children with cardiac disease from which to draw
evidence-based conclusions. There is insufficient evi-
dence to recommend the routine use of prophylactic
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